Fig 2. Survival estimates of the cumulative risk of treatment failure by Pfmdr1 alleles in patients treated with AL and ASAQ in the randomisation phase.
Fig 2(A1-A3) represent the risk of PCR-adjusted recrudescence in participants who received AL harbouring by Pfmdr1 variant. Similarly, Fig 2(B1-B3) represents the risk of PCR-adjusted recrudescence in participants who received ASAQ by Pfmdr1 variants.
